Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NKTR-102/m2 · 1 trial · 1 indication
To provide access to NKTR-102 to subjects who previously received NKTR-102 in a clinical trial and were without signs of disease progression since receiving NKTR-102.
| Arm | Type | Description |
|---|---|---|
| NKTR-102 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NKTR-102 145 mg/m2 | DRUG | A 90 minute IV infusion of 145 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle. |
| NKTR-102 120 mg/m2 | DRUG | A 90 minute IV infusion of 120 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle. |
| NKTR-102 95 mg/m2 | DRUG | A 90 minute IV infusion of 95 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle. |
| NKTR-102 50 mg/m2 | DRUG | A 90 minute IV infusion of 50 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle. |
Inclusion: 1. Received prior treatment with NKTR-102 2. Free of disease progression since receiving NKTR-102 3. Adequate bone marrow and organ function 4. Treatment with NKTR-102 in the extension study to begin within 8 weeks after receipt of their of last dose of NKTR-102 5. Agree to use adequate ...
NKTR-102, also known as etirinotecan pegol, is an investigational small molecule being studied for the treatment of advanced cancer, tumors, metastasis, malignant solid tumors, locally recurrent breast cancer, and colorectal cancer. It is in clinical development for oncology indications, including metastatic breast cancer.
NKTR-102 is a topoisomerase I inhibitor that works by targeting the enzyme topoisomerase I, which is involved in DNA replication. By inhibiting this enzyme, it is designed to interfere with cancer cell growth and division.
NKTR-102 is being developed by Nektar Therapeutics, a biopharmaceutical company. Nektar Therapeutics is publicly traded under the ticker symbol NKTR on the NASDAQ stock exchange.
NKTR-102 has completed Phase 1, Phase 2, and Phase 3 clinical trials. It is an investigational drug and has not been approved by the FDA. The completed trials include a Phase 3 study in breast cancer and a Phase 1 study in advanced cancer.
NKTR-102 has been studied in several clinical trials, including NCT01457118, an extension study in cancer patients; NCT01492101, the BEACON study in breast cancer; NCT01976143, a Phase 1 study evaluating its effect on QTc interval; and NCT02915744, a Phase 3 study in metastatic breast cancer with brain metastases.
Yes, NKTR-102 is also known as etirinotecan pegol. The drug is referred to by both names in clinical trial records and medical literature.